Chiome Bioscience and Chugai Pharmaceutical Announce Research Agreement
News Jan 09, 2009
Chiome Bioscience and Chugai Pharmaceutical Co., Ltd. have signed a joint research agreement for the generation of monoclonal antibodies against multiple target proteins chosen by Chugai Pharmaceutical.
Chiome and Chugai will develop value-added therapeutic monoclonal antibodies employing Chiome’s ADLib® (Autonomously Diversifying Library) System and will apply the System to assessment of target proteins and lead generation of products for clinical use.
Chugai will pay a contractual up-front fee to Chiome and will also pay milestones based on the results of the research. Other contractual conditions were not disclosed. Chiome and Chugai had earlier established a research collaboration agreement in July 2007. This new agreement expands the number of the targets to be addressed and extends the term of the collaboration.
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019